Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Phase 1

Conditions: Leukemia

First Posted Date: 2007-10-16

Last Posted Date: 2013-09-17

Lead Sponsor: Institut de Recherche Clinique sur les Cancers et le Sang

Target Recruit Count: 21

Registration Number: NCT00544999

Locations: 🇫🇷
Hopital Cochin, Paris, France

Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
AML
Myelodysplastic Disorders

Interventions: Drug: Idarubicin
Drug: Sorafenib
Drug: Ara-C

First Posted Date: 2007-10-12

Last Posted Date: 2018-08-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 78

Registration Number: NCT00542971

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Natural Killer Cells in Older Patients With Acute Myeloid Leukemia

Not Applicable

Completed

Conditions: Leukemia

First Posted Date: 2007-10-08

Last Posted Date: 2011-05-16

Lead Sponsor: Institut Paoli-Calmettes

Target Recruit Count: 40

Registration Number: NCT00540956

Locations: 🇫🇷
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Drug: ARA-C
Drug: BCNU
Drug: Campath-1H
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Fludarabine
Drug: Melphalan
Drug: Rituximab
Other: Allogeneic Stem Cell Transplantation
Radiation: Total body radiation (TBI)
Drug: Methotrexate
Drug: Tacrolimus
Procedure: Adback NK or T Cell

First Posted Date: 2007-09-28

Last Posted Date: 2020-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT00536978

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R

Phase 2

Active, not recruiting

Conditions: Leukemia

Interventions: Biological: aldesleukin
Biological: filgrastim
Drug: busulfan
Drug: cytarabine
Drug: etoposide
Drug: idarubicin
Procedure: autologous hematopoietic stem cell transplantation
Procedure: bone marrow transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation

First Posted Date: 2007-09-24

Last Posted Date: 2024-04-02

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 60

Registration Number: NCT00534469

Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: cytarabine
Drug: idarubicin

First Posted Date: 2007-09-12

Last Posted Date: 2017-02-06

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 111

Registration Number: NCT00528398

Locations: 🇺🇸
Banner Good Samaritan Medical Center, Phoenix, Arizona, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

LAL-BR/2001: Study Treatment to Low Risk ALL

Phase 4

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2007-09-10

Last Posted Date: 2016-01-20

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 150

Registration Number: NCT00526175

Locations: 🇪🇸
Basurtuko Ospitalea, Basurto, Spain
🇪🇸
Complejo Hospitalario Universitario de Albacete, Albacete, Spain
🇪🇸
Hospital General de Alicante, Alicante, Spain

and more 22 locations

LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia

Phase 4

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2007-09-10

Last Posted Date: 2014-10-28

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 40

Registration Number: NCT00526409

Locations: 🇪🇸
Hospital Niño Jesús, Madrid, Spain
🇪🇸
Hospital materno Infantil vall d'Hebrón, Barcelona, Spain
🇪🇸
Hospital Infantil Carlos Haya, Málaga, Spain

and more 1 locations

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Phase 4

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2007-09-10

Last Posted Date: 2010-01-05

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 100

Registration Number: NCT00526305

Locations: 🇪🇸
Hospital General de Segovia, Segovia, Spain
🇪🇸
Hospital Universitario de Canarias, Tenerife, Spain
🇪🇸
H.U. Virgen del Rocio, Sevilla, Spain

and more 46 locations

GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Biological: sargramostim
Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2007-08-27

Last Posted Date: 2015-12-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 14

Registration Number: NCT00521014

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy